The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Recombinant gp350 Vaccine for Infectious Mononucleosis: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of an Epstein‐Barr Virus Vaccine in Healthy Young Adults
Open accessAbstract
BACKGROUND: To date, there is no commercially available vaccine to prevent infectious mononucleosis, a disease frequently induced by Epstein-Barr virus (EBV) infection in adolescents or adults devoid of preexisting immunity to the virus. METHODS: A total of 181 EBV-seronegative, healthy, young adult volunteers were randomized in a double-blind fashion to receive either placebo or a recombinant EBV subunit glycoprotein 350 (gp350)/aluminum hydroxide and 3-O-desacyl-4'-monophosphoryl lipid A (AS04) candidate vaccine in a 3-dose regimen. RESULTS: The vaccine had demonstrable efficacy (mean efficacy rate, 78.0% [95% confidence interval {CI}, 1.0%-96.0%]) in preventing the development of infectious mononucleosis induced by EBV infection, but it had no efficacy in preventing asymptomatic EBV infection. One month after receipt of the final dose of gp350 vaccine, 98.7% of subjects showed seroconversion to anti-gp350 antibodies (95% CI, 85.5%-97.9%), and they remained anti-gp350 antibody positive for >18 months. Furthermore, there were no concerns regarding the safety or reactogenicity of the gp350/AS04 vaccine. CONCLUSION: These data support the clinical feasibility of using an EBV vaccine to prevent infectious mononucleosis. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00430534.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Infectious mononucleosis and risk for multiple sclerosis: A meta‐analysis
Thacker, E. L., Mirzaei, F., & Ascherio, A. (2006) · Annals of Neurology · doi:10.1002/ana.20820 · Cited by 517
Characteristics of Hodgkin's Lymphoma after Infectious Mononucleosis
Hjalgrim, H., Askling, J., Rostgaard, K., Hamilton-Dutoit, S., Frisch, M., Zhang, J.-S., Madsen, M., Rosdahl, N., Konradsen, H. B., Storm, H. H., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa023141 · Cited by 433
Crawford, D. H., Macsween, K. F., Higgins, C. D., Thomas, R., McAulay, K., Williams, H., Harrison, N., Reid, S., Conacher, M., Douglas, J., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/505400 · Cited by 209
Glaser, R., Padgett, D. A., Litsky, M. L., Baiocchi, R. A., Yang, E. V., Chen, M., Yeh, P., Klimas, N. G., Marshall, G. D., Whiteside, T. L., et al. (2004) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2004.09.001 · Cited by 125
Cited by
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Epstein–Barr virus: more than 50 years old and still providing surprises
Young, L. S., Yap, L. F., & Murray, P. G. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.92 · Cited by 856
Luzuriaga, K., & Sullivan, J. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmcp1001116 · Cited by 606
The Immunology of Epstein-Barr Virus–Induced Disease
Taylor, G. S., Long, H. M., Brooks, J. M., Rickinson, A. B., & Hislop, A. D. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112326 · Cited by 602
Farrell, P. J. (2019) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-013023 · Cited by 541
Primary Epstein-Barr virus infection
Dunmire, S. K., Verghese, P. S., & Balfour, H. H. (2018) · Journal of Clinical Virology · doi:10.1016/j.jcv.2018.03.001 · Cited by 520
Steinhagen, F., Kinjo, T., Bode, C., & Klinman, D. M. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.08.002 · Cited by 501
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives
Garçon, N., Chomez, P., & Van Mechelen, M. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.5.723 · Cited by 476
Latency and lytic replication in Epstein–Barr virus-associated oncogenesis
Münz, C. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0249-7 · Cited by 469
Epstein–Barr virus and multiple sclerosis
Soldan, S. S., & Lieberman, P. M. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00770-5 · Cited by 467
Progress and Problems in Understanding and Managing Primary Epstein-Barr Virus Infections
Odumade, O. A., Hogquist, K. A., & Balfour, H. H. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00044-10 · Cited by 458
2011: the immune hallmarks of cancer
Cavallo, F., De Giovanni, C., Nanni, P., Forni, G., & Lollini, P.-L. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0968-0 · Cited by 415
Epstein-Barr Virus: An Important Vaccine Target for Cancer Prevention
Cohen, J. I., Fauci, A. S., Varmus, H., & Nabel, G. J. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002878 · Cited by 381
Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site
Kanekiyo, M., Bu, W., Joyce, M. G., Meng, G., Whittle, J. R. R., Baxa, U., Yamamoto, T., Narpala, S., Todd, J.-P., Rao, S. S., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.043 · Cited by 366
Alum adjuvant: some of the tricks of the oldest adjuvant
Kool, M., Fierens, K., & Lambrecht, B. N. (2012) · Journal of Medical Microbiology · doi:10.1099/jmm.0.038943-0 · Cited by 318
The initiation and prevention of multiple sclerosis
Ascherio, A., Munger, K. L., & Lünemann, J. D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.198 · Cited by 289
Toll‐like receptors: the swiss army knife of immunity and vaccine development
Dowling, J. K., & Mansell, A. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.22 · Cited by 273
Balfour, H. H., Sifakis, F., Sliman, J. A., Knight, J. A., Schmeling, D. O., & Thomas, W. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit321 · Cited by 266
Epstein–Barr Virus Infection and Multiple Sclerosis: A Review
Ascherio, A., & Munger, K. L. (2010) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-010-9201-3 · Cited by 259
Nonhuman primate models of human viral infections
Estes, J. D., Wong, S. W., & Brenchley, J. M. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0005-7 · Cited by 255
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications
Bjornevik, K., Münz, C., Cohen, J. I., & Ascherio, A. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00775-5 · Cited by 246
Vaccines to Prevent Infections by Oncoviruses
Schiller, J. T., & Lowy, D. R. (2010) · Annual Review of Microbiology · doi:10.1146/annurev.micro.112408.134019 · Cited by 101
Prophylactic and therapeutic implications of toll-like receptor ligands
Hedayat, M., Takeda, K., & Rezaei, N. (2012) · Medicinal Research Reviews · doi:10.1002/med.20214 · Cited by 76
Macsween, K. F., Higgins, C. D., McAulay, K. A., Williams, H., Harrison, N., Swerdlow, A. J., & Crawford, D. H. (2010) · Clinical Infectious Diseases · doi:10.1086/650456 · Cited by 74
Epstein-Barr Virus and Multiple Sclerosis
Lünemann, J. D., & Münz, C. (2007) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-007-0038-y · Cited by 36
Metadata
- Authors
- Sokal, E. M., Hoppenbrouwers, K., Vandermeulen, C., Moutschen, M., Léonard, P., Moreels, A., Haumont, M., Bollen, A., Smets, F., & Denis, M.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-12-15
- Volume
- 196
- Issue
- 12
- Pages
- 1749-1753
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2154933177
- Cited by
- 426
- References
- 4
- FWCI
- 7.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.